

Chantiya Chanswangphuwana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9806342/publications.pdf>

Version: 2024-02-01

15
papers

68
citations

1683934

5
h-index

1588896

8
g-index

15
all docs

15
docs citations

15
times ranked

63
citing authors

#	ARTICLE	IF	CITATIONS
1	Augmentation of NK Cell Proliferation and Anti-tumor Immunity by Transgenic Expression of Receptors for EPO or TPO. <i>Molecular Therapy</i> , 2021, 29, 47-59.	3.7	11
2	Successful peripheral blood stem cell mobilization using pegfilgrastim in allogeneic stem cell transplantation. <i>International Journal of Hematology</i> , 2014, 99, 318-322.	0.7	9
3	Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. <i>Blood Advances</i> , 2022, 6, 3707-3715.	2.5	9
4	Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience. <i>Hematology</i> , 2018, 23, 385-390.	0.7	6
5	Improved Survival of Elderly-fit Patients With Acute Myeloid Leukemia Requiring Intensive Therapy: 3-Year Multicenter Analysis From TALWG. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e509-e514.	0.2	6
6	Daratumumab rapidly reduces high-titre factor VIII inhibitors in haemophilia A patients during life-threatening haemorrhages. <i>Haemophilia</i> , 2021, 27, e155-e159.	1.0	5
7	Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 450-456.	0.6	5
8	Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation. <i>Leukemia Research Reports</i> , 2022, 17, 100314.	0.2	5
9	The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3395-3403.	0.6	4
10	Types, Clinical Features, and Survival Outcomes of Patients with Acute Myeloid Leukemia in Thailand: A 3-Year Prospective Multicenter Study from the Thai Acute Leukemia Study Group (TALSG). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e635-e643.	0.2	3
11	Prognostic factors and impact of CMV reactivation on acute myeloid leukemia patients after HLA-matched myeloablative allogeneic stem cell transplantation in a high CMV prevalence country. <i>Hematology, Transfusion and Cell Therapy</i> , 2023, 45, S51-S56.	0.1	2
12	Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence From Thai Acute Myeloid Leukemia Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e915-e921.	0.2	2
13	Causes and outcomes of hypereosinophilia in a tropical country. <i>Asian Pacific Journal of Allergy and Immunology</i> , 2021, , .	0.2	1
14	Isolated Extramedullary Relapse After Human Leukocyte Antigen-Matched Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Case Reports and Literature Review. <i>Transplantation Proceedings</i> , 2021, 53, 2029-2034.	0.3	0
15	EXCELLENT PROGNOSIS OF LOW-RISK MYELOYDPLASTIC SYNDROMES (MDS) WITHOUT DETECTABLE MYELOID-RELATED MUTATIONS. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	0